Alpha Lipoic Acid Solution for Infusion

Alpha Lipoic Acid Solution for Infusion

Available presentation(s): 10 mL. Verify the exact concentration and total active quantity on the prescription and dispensing label.

Introduction: Alpha-lipoic acid (thioctic acid) is an endogenous mitochondrial cofactor and redox-active antioxidant. Parenteral use has been studied most extensively for diabetic polyneuropathy in some countries, but indications, products and dosing are jurisdiction-specific.

Dosage: There is no universally accepted New Zealand dosage for compounded alpha-lipoic acid infusion. Published neuropathy regimens have commonly studied 600 mg intravenously once daily for limited courses, but this must not be adopted without prescriber review of indication, local guidance, infusion rate and monitoring. The listed 15 mg/mL, 10 mL presentation contains 150 mg total and requires an explicit prescription and dilution/administration instruction.

Mechanisms of Action: Acts as a cofactor for mitochondrial dehydrogenase complexes; its reduced form, dihydrolipoic acid, participates in redox cycling and may regenerate other antioxidants. Proposed clinical effects include reduced oxidative stress and improved endoneurial blood flow.

Contraindications & Precautions: Avoid in known hypersensitivity. Use caution with diabetes or fasting because glucose may fall; assess thiamine status in people with alcohol dependence or malnutrition. Rapid infusion can cause nausea, headache or pressure sensations. Confirm compatibility, dilution and line requirements before administration.

Interactions: May enhance glucose-lowering therapy. Antioxidant effects could theoretically alter response to some antineoplastic regimens; oncology use requires specialist agreement. Mineral binding is possible in vitro, so avoid unvalidated admixtures.

Adverse Reactions / Side Effects: Nausea, vomiting, headache, dizziness, flushing, infusion-site irritation, hypoglycaemia and hypersensitivity have been reported. Rare serious allergic reactions are possible.

Pregnancy & Breastfeeding: Human pregnancy and lactation data for intravenous high-dose use are inadequate. Use only when the prescriber judges that benefit outweighs risk; routine wellness use is not recommended.

Storage: Store under the conditions stated on the Optimus dispensing label and product-specific worksheet. Protect from light where labelled. Do not freeze unless explicitly validated. Maintain cold chain if the label requires refrigeration. Do not use after the assigned beyond-use date or if there is visible particulate matter, precipitation, colour change, loss of container integrity or evidence of improper storage. Once entered, follow the validated in-use time; do not assume a compounded vial is multi-dose.

References

• New Zealand Formulary (NZF), current online edition; product-specific approved data sheets where available; USP Pharmaceutical Compounding—Sterile Preparations; and Optimus Healthcare validated formulation, sterility/endotoxin controls and assigned beyond-use date.
• NIH Office of Dietary Supplements. Health Professional Fact Sheets (vitamins and minerals), current online editions. https://ods.od.nih.gov/factsheets/list-VitaminsMinerals/
• US FDA. Compounding and the FDA: Questions and Answers. Updated 16 September 2025. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers